Helixmith Co., Ltd.

Helixmith Co., Ltd develops biologic and natural nutraceutical products. The company offers LAYLA Tab for osteoarthritis; Allex and Allex i for hypersensitivity improvement; and Mnemosyne for memory improvement. Its lead gene therapy product is Engensis (VM202), which is in a phase III clinical trial for diabetic peripheral neuropathy and diabetic foot ulcer; a phase II clinical trial for amyotrophic lateral sclerosis (ALS) and claudication; and a phase I clinical trial for charcot-marie-tooth disease and coronary artery disease. The company also develops VM507, an antibody that can detect and activate c-MET for chronic kidney disease; NM101 for peripheral neuropathy; NM301 for ALS; NM302; HX204 for inflammatory bowel disease; HX109 for prostate health; HX110 for respiratory health; and HX112 for climacteric women’s health. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was founded in 1996 and is based in Seoul, South Korea.